DeveloGen and Teva Enter into Exclusive License Agreement for DeveloGen's Protein Kinase B Technology for the Treatment of Cancer
DeveloGen Israel Limited ("DeveloGen"), a wholly owned subsidiary of DeveloGen AG, today announced that DeveloGen, throu…